Literature DB >> 33628836

Diabetic Retinopathy Screening in Patients with Diabetes Using a Handheld Fundus Camera: The Experience from the South-Eastern Region in Hungary.

Dóra Júlia Eszes1, Dóra Júlia Szabó2, Greg Russell3, Csaba Lengyel4, Tamás Várkonyi4, Edit Paulik1, László Nagymajtényi1, Andrea Facskó2, Goran Petrovski5, Beáta Éva Petrovski5.   

Abstract

PURPOSE: Diabetic retinopathy (DR) is the leading cause of vision loss among active adults in industrialized countries. We aimed to investigate the prevalence of diabetes mellitus (DM), DR and its different grades, in patients with DM in the Csongrád County, South-Eastern region, Hungary. Furthermore, we aimed to detect the risk factors for developing DR and the diabetology/ophthalmology screening patterns and frequencies, as well as the effect of socioeconomic status- (SES-) related factors on the health and behavior of DM patients.
METHODS: A cross-sectional study was conducted on adults (>18 years) involving handheld fundus camera screening (Smartscope Pro Optomed, Finland) and image assessment using the Spectra DR software (Health Intelligence, England). Self-completed questionnaires on self-perceived health status (SPHS) and health behavior, as well as visual acuity, HbA1c level, type of DM, and attendance at healthcare services were also recorded.
RESULTS: 787 participants with fundus camera images and full self-administered questionnaires were included in the study; 46.2% of the images were unassessable. T1D and T2D were present in 13.5% and 86.5% of the participants, respectively. Among the T1D and T2D patients, 25.0% and 33.5% had DR, respectively. The SES showed significant proportion differences in the T1D group. Lower education was associated with a lower DR rate compared to non-DR (7.7% vs. 40.5%), while bad/very bad perceived financial status was associated with significantly higher DR proportion compared to non-DR (63.6% vs. 22.2%). Neither the SPHS nor the health behavior showed a significant relationship with the disease for both DM groups. Mild nonproliferative retinopathy without maculopathy (R1M0) was detected in 6% and 23% of the T1D and T2D patients having DR, respectively; R1 with maculopathy (R1M1) was present in 82% and 66% of the T1D and T2D groups, respectively. Both moderate nonproliferative retinopathy with maculopathy (R2M1) and active proliferative retinopathy with maculopathy (R3M1) were detected in 6% and 7% of the T1D and T2D patients having DR, respectively. The level of HbA1c affected the attendance at the diabetology screening (HbA1c > 7% associated with >50% of all quarter-yearly attendance in DM patients, and with 10% of the diabetology screening nonattendance).
CONCLUSION: The prevalence of DM and DR in the studied population in Hungary followed the country trend, with a slightly higher sight-threatening DR than the previously reported national average. SES appears to affect the DR rate, in particular, for T1D. Although DR screening using handheld cameras seems to be simple and dynamic, much training and experience, as well as overcoming the issue of decreased optic clarity is needed to achieve a proper level of image assessability, and in particular, for use in future telemedicine or artificial intelligence screening programs.
Copyright © 2021 Dóra Júlia Eszes et al.

Entities:  

Mesh:

Year:  2021        PMID: 33628836      PMCID: PMC7884113          DOI: 10.1155/2021/6646645

Source DB:  PubMed          Journal:  J Diabetes Res            Impact factor:   4.011


  23 in total

Review 1.  Diabetic retinopathy screening: a systematic review of the economic evidence.

Authors:  S Jones; R T Edwards
Journal:  Diabet Med       Date:  2010-03       Impact factor: 4.359

Review 2.  Screening and prevention of diabetic blindness.

Authors:  E Stefánsson; T Bek; M Porta; N Larsen; J K Kristinsson; E Agardh
Journal:  Acta Ophthalmol Scand       Date:  2000-08

3.  A cross-sectional survey of self-perceived health status and metabolic control values in patients with type 2 diabetes.

Authors:  Asiye Kartal; Fadime Hatice İnci
Journal:  Int J Nurs Stud       Date:  2010-08-03       Impact factor: 5.837

4.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

5.  Impact of Socioeconomic Disadvantage and Diabetic Retinopathy Severity on Poor Ophthalmic Follow-Up in a Rural Vermont and New York Population.

Authors:  Jeremy J Peavey; Samantha L D'Amico; Brian Y Kim; Stephen T Higgins; David S Friedman; Christopher J Brady
Journal:  Clin Ophthalmol       Date:  2020-08-21

6.  Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic conditions.

Authors:  Maaike Langelaan; Michiel R de Boer; Ruth M A van Nispen; Bill Wouters; Annette C Moll; Ger H M B van Rens
Journal:  Ophthalmic Epidemiol       Date:  2007 May-Jun       Impact factor: 1.648

7.  Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050.

Authors:  Jinan B Saaddine; Amanda A Honeycutt; K M Venkat Narayan; Xinzhi Zhang; Ron Klein; James P Boyle
Journal:  Arch Ophthalmol       Date:  2008-12

8.  Predictors of Photographic Quality with a Handheld Nonmydriatic Fundus Camera Used for Screening of Vision-Threatening Diabetic Retinopathy.

Authors:  Jose R Davila; Sabyasachi S Sengupta; Leslie M Niziol; Manavi D Sindal; Cagri G Besirli; Swati Upadhyaya; Maria A Woodward; Rengaraj Venkatesh; Alan L Robin; Joseph Grubbs; Paula Anne Newman-Casey
Journal:  Ophthalmologica       Date:  2017-07-05       Impact factor: 3.250

Review 9.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.

Authors:  Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

10.  Socio-economic factors and diabetes consequences among patients with type 2 diabetes.

Authors:  Azar Tol; Gholamreza Sharifirad; Davoud Shojaezadeh; Elahe Tavasoli; Leila Azadbakht
Journal:  J Educ Health Promot       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.